The $7B Healthcare Bet + AI’s Next Platform Layer

Good morning, ! Today we're tracking where healthcare's next infrastructure is being built. Investors are betting on AI-powered clinical decision support over virtual care, Warburg Pincus just made a ~$7B commitment to specialty pharmacy, and a new Ebola outbreak is reminding the world that the biggest risk isn't always the virus—it's failing to detect it.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

Clinical Decision Support Is Emerging as Digital Health’s Platform Layer

When asked which digital health category is most likely to produce the next $10B company, readers overwhelmingly chose Clinical Decision Support (54%), well ahead of Virtual Care Platforms (30%) and Remote Patient Monitoring (16%).

The result reflects a broader shift in digital health investing. Access-based models have largely matured, and investors are increasingly prioritizing technologies that improve clinical productivity and decision-making rather than simply expanding care delivery channels.

Clinical decision support sits at the intersection of healthcare's two largest pain points: physician shortages and administrative burden. As generative AI matures and health systems demand measurable ROI, tools that augment clinician workflows, reduce documentation friction, and improve diagnostic accuracy are increasingly being viewed as infrastructure rather than point solutions.

The relatively low support for RPM is notable. Despite strong market growth projections, many operators still view remote monitoring as a feature embedded within broader care platforms instead of a standalone category capable of producing venture-scale outcomes.

Bottom line: The market increasingly believes healthcare's next decacorn won't be built on virtual visits or connected devices. It will be built on becoming the intelligence layer that sits inside every clinical decision. (More)

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here

HEADLINE OF THE WEEK

Ebola's New Threat Is Not Mortality. It's Invisibility.

The latest Ebola outbreak in the Democratic Republic of Congo is exposing a dangerous reality: the biggest risk is no longer the virus itself, but the inability to see where it's spreading.

According to the WHO, 80% of new Ebola cases in the outbreak's epicenter have no known link to existing patients, suggesting community transmission is occurring largely outside formal surveillance networks. More concerning, modeling indicates the outbreak could be 2 to 4 times larger than official figures of 1,792 cases and 625 deaths.

The epidemiology is unusual. Preliminary evidence suggests the Bundibugyo strain may produce milder symptoms than previous Ebola variants. While this appears to improve survival rates, it may also reduce risk perception, causing infected individuals to remain in their communities longer and unknowingly spread the virus.

The numbers are alarming. Roughly 50% of people tested in Bunia are positive for Ebola, and approximately 70% of early deaths occurred outside treatment centers.

Why it matters: The outbreak is a reminder that surveillance infrastructure remains one of global health's weakest links. The next generation of outbreak response may depend less on vaccines and therapeutics and more on real-time diagnostics, community health networks, and digital disease surveillance systems capable of detecting transmission before it disappears into the population.

Bottom line: COVID taught the world the cost of late detection. Congo's Ebola outbreak is showing that in infectious disease, what you cannot see can still spread rapidly. (More)

DEAL OF THE WEEK

Warburg Pincus Doubles Down on Specialty Pharmacy with ~$7B PANTHERx Rare Deal

Private equity continues to chase healthcare businesses with recurring revenue and defensible positioning. This week, a Warburg Pincus-led investor group agreed to acquire a controlling stake in PANTHERx Rare in a transaction reportedly valued at approximately $7 billion, making it one of the largest healthcare buyouts of the year. Existing investors Nautic Partners, General Atlantic, and The Vistria Group are exiting part of their positions, while Nautic and management will retain meaningful ownership.

Why does this matter? PANTHERx operates in one of healthcare's most attractive niches: rare disease specialty pharmacy. As orphan drug approvals continue to accelerate, manufacturers increasingly rely on highly specialized pharmacy partners capable of navigating complex reimbursement pathways, patient support programs, and high-touch care coordination. These businesses have become critical infrastructure rather than simple drug distributors.

The bottom line: The deal reinforces a broader investment thesis: the value is shifting toward healthcare intermediaries that sit between innovative therapies and patients. As the rare disease pipeline expands, expect specialty pharmacy platforms to remain among private equity's highest-conviction bets. Read more.

DEAL TRACKER

Edgewise Therapeutics → Servier | $1.55B upfront + $1.1B milestones

Acquisition — Servier completes $2.65B deal for Edgewise's late-stage Becker/Duchenne muscular dystrophy pipeline, anchored by sevasemten. Read more.

Myricx Bio → Novartis | ~$1.5B ($1.1B upfront + $400M milestones)

Biotech M&A — Novartis acquires UK-based Myricx Bio for its next-gen antibody-drug conjugate platform using NMT inhibitor payloads, bolstering its ADC pipeline. Read more.

MatrixCare → Frazier Healthcare Partners (from ResMed) | $490M

PE Carve-out — Frazier acquires ResMed's home-health and senior-care EHR platform (~$220M revenue) as ResMed refocuses on its core device business. Read more.

REGIONAL FOCUS

Why Global Biopharma Is More Optimistic Than the US

While headlines often focus on the dominance of the U.S. biotech ecosystem, executive sentiment suggests a more nuanced picture. According to Deloitte's 2026 Life Sciences Executive Outlook, 90% of non-U.S. biopharma executives are positive or cautiously positive about the industry's outlook for 2026, compared with just 56% of their U.S. counterparts. Meanwhile, more than one in four U.S. executives describe their outlook as negative or uncertain.

The confidence gap reflects diverging priorities rather than diverging opportunities. U.S. executives remain focused on policy uncertainty, pricing pressures, and evolving regulatory dynamics, while companies outside the U.S. appear more confident in their ability to drive growth through innovation, AI adoption, strategic partnerships, and international expansion. As capital allocation becomes increasingly selective, optimism itself can become a competitive advantage—shaping hiring, R&D investment, and M&A activity.

Why it matters: While the U.S. remains the world's largest life sciences market, investor confidence is becoming increasingly global. The next wave of innovation—and dealmaking—may be driven as much by international momentum as by American leadership. Read more.

INTERESTING ARTICLES